Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466097 | 0.88 | KDM4E (0.52) | KDM4EPOLBKEAP1CYP1A2CYP3A4 | |
| SCHEMBL25279294 | 0.88 | KDM4E (0.52) | KDM4EPOLBKEAP1CYP1A2CYP3A4 | |
| SCHEMBL12593846 | 0.87 | KEAP1 (0.62) | KDM4EPOLBKEAP1CYP1A2CYP3A4 | |
| SCHEMBL8122877 | 0.87 | HSPB1 (0.51) | KDM4EPOLBKEAP1CYP1A2CYP3A4 | |
| SCHEMBL4065605 | 0.84 | KEAP1 (0.59) | KDM4EPOLBKEAP1CYP3A4MEN1 | |
| SCHEMBL1200417 | 0.84 | KDM4E (0.52) | KDM4EPOLBKEAP1MEN1KMT2A | |
| SCHEMBL15684805 | 0.82 | CYP1A2 (0.46) | KDM4EPOLBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4070182 | 0.82 | KEAP1 (0.60) | KDM4EPOLBKEAP1MEN1KMT2A | |
| SCHEMBL4060269 | 0.82 | CYP3A4 (0.55) | POLBCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL4064001 | 0.81 | KDM4E (0.63) | KDM4EPOLBKEAP1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-6861420-B2 | N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1451176-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030149024-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-07 | — | — | US | disclosed |
| WO-2003045940-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
| US-6458813-B1 | 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER | AMGEN INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | disclosed |
| US-6333341-B1 | TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS | AMGEN INC. | 2001-12-25 | — | — | US | disclosed |
| US-6184237-B1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | IL1B, IL6, IL1A | KDM4E 1937/4885POLB 3027/4885KEAP1 334/4885 |
| US-20030149024-A1 | Therapeutic compounds | REN, HMGCR, RPS4X | KDM4E 2934/4885POLB 3496/4885KEAP1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.